Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

K. Stamatopoulos | D. Lad | T. Chatzikonstantinou | G. Gaidano | Š. Pospíšilová | A. Cuneo | A. Kater | D. Oscier | Z. Davis | M. Angelopoulou | G. Pangalis | R. Moia | C. Tam | E. Hatzimichael | M. Catherwood | B. Espinet | J. Labrador | M. Šimkovič | A. Gogia | R. Kreitman | L. Trentin | M. Špaček | M. Alcoceba | L. Laurenti | Y. Herishanu | M. Levin | P. Ghia | N. Stavroyianni | B. Biderman | E. Minga | L. Scarfò | P. Panagiotidis | P. Sportoletti | J. Kotaskova | M. Coscia | G. Rigolin | A. Gozzetti | A. Fresa | F. Bijou | Julia von Tresckow | G. Reda | R. Cassin | F. Demirkan | J. Marquet | J. Olivieri | I. Levy | T. Papajík | L. Smolej | A. López-García | D. Antić | J. Hernández‐Rivas | F. Miras | R. Walewska | E. Wąsik-Szczepanek | B. Mihaljević | K. Tomic | M. Morawska | A. Chatzidimitriou | L. Yáñez | T. Tadmor | G. Iacoboni | V. Karakuş | C. Vitale | A. Visentin | R. Ruchlemer | G. Vrachiolias | Yandong Shen | J. Zuchnická | E. Gimeno | Bonnie Kho | M. Maynadié | A. Navarro-Bailón | Á. Medina | Sean Harrop | V. Popov | S. Chatzileontiadou | M. Schipani | E. Konstantinou | R. Murru | Valerio Guarente | L. Rani | U. Nath | A. Puiggros | S. El-Ashwah | Francesca Bacchiarri | Zhenshu Xu | M. Kislova | Stanislava Mašlejová | E. Kalicińska | M. Efstathopoulou | R. García-Serra | O. Kalashnikova | J. von Tresckow | A. Galitzia | Punyarat Phumphukhieo | I. González-Gascón-Y-Marín | Thomas Longval | B. Dreta | Georgios Karakatsoulis | C. Pierie | Dimitra Chamou | Annett Schiwitza | David Donaldson | T. Aurran-Schleinitz | Ana C. Oliveira | Francesc Bosch | Romain Guièze | Ioannis Kotsianidis | Maya Koren-Michowitz | Eric Tse | I. Panovska-Stavridis | O. Jakšić | Vojin Vuković | M. Doubek | C. Demosthenous | Stephen P Mulligan | Salem Al-Shemari | Mar Bellido | Anne Calleja | Mehreen Ali Khan | Rosa Collado | Amy Christian | Maria Dimou | Gimena Dos Santos | Alicia I. Enrico | Sara Galimberti | Ritu Gupta | Luca Inchiappa | Susanne Janssen | Laribi Kamel | Lucia Martin-Rodríguez | Carlota Mayor-Bastida | Ivana Milosevic | Maria Papaioannou | Zuzana Kubova | Marcos Daniel de Deus Santos | S. Smirnova | Dina Sameh Abdelrahman Soliman | Theodoros Vassilakopoulos | Münci Yağci | Mohamed A. Yassin | Rainer Claus | Eugene Nikitin | M. Bellido | Münci Yağcı | S. Galimberti | Ivana Milošević

[1]  L. Morton,et al.  Trends in risk for therapy-related myelodysplastic syndrome/acute myeloid leukemia after initial chemo/immunotherapy for common and rare lymphoid neoplasms, 2000–2018 , 2023, EClinicalMedicine.

[2]  A. Langerak,et al.  Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019 , 2023, Blood Cancer Journal.

[3]  T. Shanafelt,et al.  Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial , 2022, Blood.

[4]  K. Stamatopoulos,et al.  Clonal haematopoiesis as a risk factor for therapy‐related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo‐(immuno)therapy , 2022, British journal of haematology.

[5]  M. Hallek,et al.  Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Rostgaard,et al.  Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population‐based study , 2021, British journal of haematology.

[7]  Qi Wang,et al.  Leukemia incidence trends at the global, regional, and national level between 1990 and 2017 , 2020, Experimental Hematology & Oncology.

[8]  M. Hallek,et al.  Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials , 2020, Leukemia.

[9]  F. Maura,et al.  Second malignancies in multiple myeloma; emerging patterns and future directions. , 2020, Best practice & research. Clinical haematology.

[10]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[11]  A. Chanan-Khan,et al.  Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia , 2019, Blood Cancer Journal.

[12]  M. Grever,et al.  Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors , 2019, Leukemia.

[13]  J. Gea-Banacloche,et al.  Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections. , 2018, Blood reviews.

[14]  J. Byrd,et al.  iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. , 2018, Blood.

[15]  I. Keilegom,et al.  Cure Models in Survival Analysis , 2018 .

[16]  Megan E. McNerney,et al.  Therapy-related myeloid neoplasms: when genetics and environment collide , 2017, Nature Reviews Cancer.

[17]  J. Zandbank,et al.  Chemotherapy may eradicate ductal carcinoma in situ (DCIS) but not the associated microcalcifications. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  L. Trentin,et al.  Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients. , 2017, European journal of cancer.

[19]  E. Campo,et al.  Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors , 2016, Haematologica.

[20]  S. Strom,et al.  Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  J. Cerhan,et al.  Risk of Non-hematologic Cancer in Individuals with High Count Monoclonal B-Cell Lymphocytosis (MBL) , 2015, Leukemia.

[22]  P. Moss,et al.  Perturbation of the normal immune system in patients with CLL. , 2015, Blood.

[23]  Z. Estrov,et al.  Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes , 2015, Leukemia & lymphoma.

[24]  P. Glasziou,et al.  Prevalence of incidental prostate cancer: A systematic review of autopsy studies , 2015, International journal of cancer.

[25]  J. Cerhan,et al.  Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Chiaretti,et al.  The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1. , 2012, Leukemia supplements.

[27]  T. McDonnell,et al.  Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma , 2012, Modern Pathology.

[28]  P. Baade,et al.  Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study , 2011, British Journal of Cancer.

[29]  M. Čolović,et al.  Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide. , 2011, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[30]  L. Pasqualucci,et al.  Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation , 2011, The Journal of experimental medicine.

[31]  Pedro M. Valero-Mora,et al.  ggplot2: Elegant Graphics for Data Analysis , 2010 .

[32]  David Firth,et al.  Bias reduction in exponential family nonlinear models , 2009 .

[33]  Francesco Bertoni,et al.  Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome , 2009, Clinical Cancer Research.

[34]  H. Kantarjian,et al.  Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  G. Haas,et al.  The role of prevalence in the diagnosis of prostate cancer. , 2006, Cancer control : journal of the Moffitt Cancer Center.

[36]  K. Do,et al.  Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  V. Morrison,et al.  Infectious complications of chronic lymphocytic leukemia. , 2006, Seminars in oncology.

[38]  F. Ravandi,et al.  Immune defects in patients with chronic lymphocytic leukemia , 2006, Cancer Immunology, Immunotherapy.

[39]  H. Zou,et al.  Addendum: Regularization and variable selection via the elastic net , 2005 .

[40]  Lois Shepherd,et al.  Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Greene,et al.  Solid tumors after chronic lymphocytic leukemia. , 2001, Blood.

[42]  R. Foà,et al.  Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. , 1999, Blood.

[43]  M. Hallek,et al.  Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  L. Pasqualucci,et al.  Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. , 2013, Blood.

[45]  J. Baars,et al.  Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study. , 2006, Haematologica.